Narcolepsy – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Narcolepsy – Pipeline Review, H1 2020’, provides an overview of the Narcolepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Narcolepsy

– The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects

– The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Narcolepsy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Narcolepsy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Avadel Pharmaceuticals Plc

Axsome Therapeutics Inc

Balance Therapeutics Inc

Bioprojet SCR

F. Hoffmann-La Roche Ltd

Inexia Ltd

Jazz Pharmaceuticals Plc

NLS Pharma Group

Ono Pharmaceutical Co Ltd

Orexia Ltd

Seelos Therapeutics, Inc.

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Vallon Pharmaceuticals Inc

XW Laboratories Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Narcolepsy - Overview

Narcolepsy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Narcolepsy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Narcolepsy - Companies Involved in Therapeutics Development

Avadel Pharmaceuticals Plc

Axsome Therapeutics Inc

Balance Therapeutics Inc

Bioprojet SCR

F. Hoffmann-La Roche Ltd

Inexia Ltd

Jazz Pharmaceuticals Plc

NLS Pharma Group

Ono Pharmaceutical Co Ltd

Orexia Ltd

Seelos Therapeutics, Inc.

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

Theranexus SAS

Vallon Pharmaceuticals Inc

XW Laboratories Inc

Narcolepsy - Drug Profiles

(flecainide acetate + modafinil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dextroamphetamine IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oxybate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reboxetine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5256390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNG-3031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-994 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XWL-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Narcolepsy - Dormant Projects

Narcolepsy - Discontinued Products

Narcolepsy - Product Development Milestones

Featured News & Press Releases

Mar 30, 2020: Harmony Biosciences highlights publication Of narcolepsy treatment scientific review in sleep medicine

Mar 25, 2020: Avadel Pharmaceuticals completes the REST-ON Phase 3 Pivotal trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Mar 25, 2020: Jazz Pharmaceuticals announces FDA acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jan 22, 2020: Jazz Pharmaceuticals submits new drug application for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy

Dec 17, 2019: Avadel Pharmaceuticals completes enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Dec 03, 2019: Axsome Therapeutics announces AXS-12 achieves primary endpoint in CONCERT phase 2 trial in Narcolepsy

Dec 02, 2019: Avadel Pharmaceuticals announces key appointments to leadership team to support continued transformation and the advancement of FT218

Nov 25, 2019: Avadel Pharmaceuticals achieves enrollment target in REST-ON phase 3 pivotal trial of FT218 for excessive daytime sleepiness and Cataplexy in patients with Narcolepsy

Nov 20, 2019: Harmony Biosciences announces publication of data in sleep from two clinical studies of WAKIX (pitolisant)

Oct 21, 2019: Axsome Therapeutics completes patient enrollment in the CONCERT Phase 2 trial of AXS-12 in narcolepsy

Oct 02, 2019: Axsome Therapeutics to Provide Update on AXS-12 at the 2019 Cantor Global Healthcare Conference

Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress

Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1

Sep 25, 2019: Jazz Pharmaceuticals presents positive JZP-258 phase 3 study data at World Sleep 2019

Sep 24, 2019: First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Narcolepsy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Narcolepsy – Pipeline by Avadel Pharmaceuticals Plc, H1 2020

Narcolepsy – Pipeline by Axsome Therapeutics Inc, H1 2020

Narcolepsy – Pipeline by Balance Therapeutics Inc, H1 2020

Narcolepsy – Pipeline by Bioprojet SCR, H1 2020

Narcolepsy – Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Narcolepsy – Pipeline by Inexia Ltd, H1 2020

Narcolepsy – Pipeline by Jazz Pharmaceuticals Plc, H1 2020

Narcolepsy – Pipeline by NLS Pharma Group, H1 2020

Narcolepsy – Pipeline by Ono Pharmaceutical Co Ltd, H1 2020

Narcolepsy – Pipeline by Orexia Ltd, H1 2020

Narcolepsy – Pipeline by Seelos Therapeutics, Inc., H1 2020

Narcolepsy – Pipeline by Suven Life Sciences Ltd, H1 2020

Narcolepsy – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Narcolepsy – Pipeline by Theranexus SAS, H1 2020

Narcolepsy – Pipeline by Vallon Pharmaceuticals Inc, H1 2020

Narcolepsy – Pipeline by XW Laboratories Inc, H1 2020

Narcolepsy – Dormant Projects, H1 2020

Narcolepsy – Dormant Projects, H1 2020 (Contd..1), H1 2020

Narcolepsy – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Narcolepsy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports